Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo CAR-T therapy targets multiple cancer proteins

NCT ID NCT03125577

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a combination of genetically modified immune cells (CAR-T cells) that target CD19 plus another protein on B-cell cancers. The goal is to improve treatment for patients whose cancer has returned or not responded to standard therapy. The study enrolls 100 participants across multiple centers and is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
genetically modified immune cells (CAR-T cells) targeting CD19 plus one of CD20, CD22, CD30, CD38, CD70, or CD123
What this could lead to
If it works, this could offer a more effective treatment option for patients with B-cell cancers that have come back or not responded to standard therapy.
What could go wrong
This is an early phase 1/2 trial with only 100 participants, so results are preliminary. CAR-T therapy can cause severe side effects like cytokine release syndrome and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm Leukemia, B-Cell

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL MALIGNANCIES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shenzhen Geno-immune Medical Institute

    RECRUITING

    Shenzhen, Guangdong, 518000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.